AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05400174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tilt table (upright position)
Description: Different versions of cognitive assessments will be administered in the supine and upright positions.
Study NCT06016075 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hyperpolarised MRI
Description: Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. Non-radioactive, no risk, approved for use in humans.
Study NCT06016075 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sodium MRI
Description: MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium.
Study NCT06016075 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Deuterium metabolic imaging (DMI) MRI
Description: Drink of a sugar drink 90min before the MRI scan. Non-radioactive, no risk, approved for use in humans.
Study NCT06060210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: 50-ml Saline
Study NCT06060210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 50-ml volumes, and the ketamine concentration is 1 mg/ml
Study NCT05196308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH)
Description: Administration of the investigational product.~For the double-blind treatment phase, experimental group :~Patients will receive Xeomin® (MERZ PHARMACEUTICALS GMBH), 100 U, a paired intracavernosal injection to be performed by the investigator.
Study NCT05196308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: For the double-blind treatment phase, control group :~Patients will receive placebo of Xeomin® 100 U, a paired intracavernosal injection is to be performed by the investigator.
Study NCT04812418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Noctesia
Description: 3 tablets every day at bedtime with a large glass of water
Study NCT04812418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets every day at bedtime with a large glass of water
Study NCT05091892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy programm
Description: Treatment
Study NCT05724420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRIVE course delivery
Description: STRIVE is adapted from the Road to Mental Readiness curriculum, developed by the Department of National Defence in Canada. It is comprised of a 4-hour formal education session where participants are provided knowledge, skills and resources specific to self-assessment for mental wellness and effective mindfulness strategies. High fidelity simulation sessions are then utilized to reinforce and apply mindfulness techniques learned in the formal session..
Study NCT04917224 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Adaptive Ablative Radiotherapy at 50 Gy (Gray)
Description: Cohort A will include 30 patients with central tumors; the dose regimen prescribed is 50 Gy (Gray) in 5 fractions with a 40 hour inter-fraction interval.
Study NCT04917224 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Adaptive Ablative Radiotherapy at 60 Gy (Gray)
Description: Cohort B will include 30 patients with ultra-central tumors; the dose regimen prescribed is 60 Gy (Gray) in 8 fractions on consecutive days.
Study NCT05731999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previct Drugs
Description: Previct Drugs is a new non CE-marked eHealth system intended to be used for future monitoring and treatment of patients with substance use disorder (SUD). Previct Drugs consists of an application (app) to be installed on a smartphone, a web-based careportal to be accessed from a computer by the healthcare professional for administration and access of registered data, and a database for storage, handling, and analysis of reported data. Previct Drugs is intended to be used by healthcare professionals and patients within treatment of SUD.
Study NCT05801653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT05801653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of Oat and Oat Components on Cardiometabolic risk variables
Description: Oat and oat bioactive components consumed as breakfast meal.
Study NCT06226688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback device and other group control group
Description: Intervention 1 :-Using the biofeedback device with dumble to strength affected arm post mastectomy
Study NCT06226688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Shoulder mobilization Shoulder ladder ex Shoulder wheel ex Ipc
Study NCT05656898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezocision+GaALAs diode laser
Description: After seven weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied on each tooth of the six maxillary anterior teeth .
Study NCT05656898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Vertical soft-tissue incisions will be made on the buccal and palatal gingiva. One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars.
Study NCT05656898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic fixed appliance
Description: Closed nickel-titanium coil springs applying 250 g of force per side will be used for retraction of the maxillary anterior teeth.
Study NCT06372054 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of biological samples (blood, urine, saliva) and clinical data
Study NCT05955495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food
Description: Post-operative feeding includes water, liquid diet, soft diet.
Study NCT05955495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Post-operative feeding includes water, liquid diet, soft diet.
Study NCT06273787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic release
Description: diaphragmatic myofascial release for 1 months 3 sessions per week
Study NCT06273787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diaphragmatic release
Description: diaphragmatic myofascial release for 1 months 3 sessions per week
Study NCT06446310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLG2198
Description: Participants receive QLG2198 three times a week (0,5 micrograms/kg dry body weight). QLG21988 is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis.
Study NCT06446310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive Placebo three times a week (0,5 micrograms/kg dry body weight). Placebo is administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each dialysis
Study NCT05409248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive stimulation
Description: Online gamified activities designed to stimulate cognitive functions (specifically executive function) will be carried out through a mobile application or web browser. Performance feedback will be shown after each activity.
Study NCT05180968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone 0.5 MG Oral Capsule
Description: This intervention will consist of subjects receiving nabilone 0.5 mg orally at night for 1 week increased to nabilone 0.5mg orally twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
Study NCT05180968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nabilone
Description: This intervention will consist of subjects receiving placebo 1 capsule orally at night for 1 week increased to placebo 2 capsules twice a day for 3 weeks. Duration of the intervention will be 4 weeks.
Study NCT05157724 — intervention group
Intervention type: PROCEDURE
Intervention: PLASMA
Description: The aim is to remove the prostatic adenoma by enucleation, i.e. to pass through the plane between the adenoma and the prostatic capsule, as opposed to resection, which also consists of removing the adenoma, but by making small cuts in the prostatic tissue, without necessarily reaching this anatomical plane between the adenoma and the capsule. This means removing less adenoma and therefore increasing the risk of adenomatous regrowth in the long term or obtaining worse results than enucleation in the short to medium term.~The other advantage of using this approach is that it reduces intra- and post-operative bleeding and does not require the systematic discontinuation of anti-aggregating or anticoagulant treatments prior to the operation. The field of indications is thus potentially enlarged.
Study NCT04564430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catapresan
Description: The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
Study NCT04564430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: controlgroup receiving saline
Study NCT03886025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive brain stimulation
Study NCT01058252 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: INVOCell, Letrozole 2.5 mg, recFSH 75 IU
Description: OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~* Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~* Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).~* Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~* On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~* Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder.
Study NCT01058252 — intervention group
Intervention type: PROCEDURE
Intervention: STEP-3: LH Suppression & Monitoring
Description: Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle.
Study NCT01058252 — intervention group
Intervention type: PROCEDURE
Intervention: STEP-4: HCG Timing
Description: IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~* E2 level is over 150 pg/ml/per mature follicle (> 15 mm)~* Domminent follicle is greater than 18 mm in mean diameter~* LH Remains as Baseline, OR~* The day when Urinary LH Surge is positive
Study NCT01058252 — intervention group
Intervention type: PROCEDURE
Intervention: STEP-5: OPU, ET, Cancellation
Description: Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~* Poor patient compliance~* Premature Ovulation~* Premature LH Surge~* Endometrium \< 7 mm~* Poor Follicular Development~* E2 Level > 2,500 pg/ml
Study NCT01058252 — intervention group
Intervention type: PROCEDURE
Intervention: INVOCell (Intravaginal Culturing)
Description: Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 100000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
Study NCT05409248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham cognitive stimulation
Description: Non-therapeutic online games based on artistic tasks designed to not train the specific cognitive abilities at test. The time of each session will match that of the experimental group. Performance feedback will be shown after each game.
Study NCT03886025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Iowa Gambling Task will be used for cognitive training
Study NCT03886025 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: Iowa Gambling Task will be used for cognitive training
Study NCT03886025 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation (tDCS)
Description: Non-invasive brain stimulation
Study NCT06342323 — intervention group
Intervention type: RADIATION
Intervention: SBRT
Description: the fiducial marker was implanted with 3D template assistance under CT guidance
Study NCT05997017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients
Study NCT04565418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: 3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions
Study NCT06502275 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Management Frailty Care Program
Description: Through the LINE communication software, participants are provided with exercise and nutrition information three times a week, with a total of 36 messages. As well as 6 podcasts of health information and 6 sports videos in total. At weeks 2, 4, and 6, researchers scheduled 5- to 10-minute telephone consultations. Participants can receive guidance through telephone consultations and carry a Xiaomi sports band wearable device to monitor their exercise.
Study NCT05369078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 20mg Single dose
Description: THR-1442 20mg is administrated 1 dose on Day 1, then follow till day 7.
Study NCT05369078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-1442 20mg Multiple dose group
Description: THR-1442 20mg is administrated QD for 7days, then follow till day 14.
Study NCT05101226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga attended in person
Description: One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study NCT05467319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Derisomaltose Injection
Description: 1000mg of ferric derisomaltose in 100mL of normal saline by intravenous infusion
Study NCT05467319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 100 mL of 0.9% normal saline (w/v) by intravenous infusion
Study NCT05101226 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga attended in person
Description: One or two weekly yoga classes taught and attended in person with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study NCT05101226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga attended online
Description: One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study NCT05101226 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga attended online
Description: One or two weekly yoga classes taught and attended online with a duration of 60 minutes each. The participants can chose if they want to attend one or both classes. The classes will start with a 10 minute Warm Up and a short Meditation, 10 minutes Sun Salutations, 15 minutes standing Asanas, 15 minutes sitting and lying Asanas and 10 minutes Shavasanah and Meditation.
Study NCT04700280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: GLPG3970 film-coated tablet.
Study NCT05992129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: foot exercise
Description: These are foot and ankle muscle strengthening exercises described and evaluated by the literature
Study NCT04700280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo film-coated tablet.
Study NCT06335823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit turned on and half will have the TENS unit turned on to a 80 hz preset frequency with 100 mA as the pulse width.
Study NCT06335823 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transcutaneous electrical nerve stimulation (TENS)
Description: All patients will have the TENS unit applied: 2 pads from channel 1 will be at T10-L1 and the second set of pads will be from S2-S4; 5 minutes prior to the start of the procedure. Patients will have the TENS unit will not be turned on.
Study NCT06364644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Champions
Description: The UNLOAD-Heart Failure Program intervention includes problem solving training, community health worker support, and exercise support from health coaches at YMCAs.
Study NCT06364644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Homegrown Heroes
Description: Monthly newsletters/videos on diabetes self-management, healthy lifestyle and heart failure prevention will be provided, as well as a membership to the local YMCA.
Study NCT05807178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Light Therapy Device, LSA-1
Description: Dynamic Light Therapy
Study NCT05807178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Light Therapy Device, LSA-2
Description: Dynamic Light Therapy
Study NCT05414292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamune (sirolimus) 1Mg Tablet
Description: Take Rapamune to see the effect on muscle structure and function during a 14 week unilateral resistance exercise training programme.
Study NCT05414292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise training
Description: Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
Study NCT05414292 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unilateral resistance exercise training
Description: Participants will complete unilateral leg extension resistance training 3 times per week for 14 weeks at 75% of their 1 repetition maximum
Study NCT06108349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
Study NCT05075083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive two doses inactivated COVID-19 vaccine with the interval of 21 days
Study NCT05890885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Real left prefrontal tDCS - sham
Description: Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period
Study NCT04750044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early refeeding
Description: In the early refeeding group, oral diet is started 24 hours after PEP is confirmed. The oral diet starts with SOW (Sips of water) and builds up sequentially in the order of clear liquid diet-soft diet, considering patient tolerability.